Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine

Hanxiao Xu, Ying Jiao, Shuang Qin, Weiheng Zhao, Qian Chu* and Kongming Wu*

Abstract
Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases, such as infectious diseases, genetic abnormality and even cancers. In addition, organoids can more accurately predict drug responses, and serve as an excellent platform for drug development, including efficacy evaluation, toxicity testing and pharmacokinetics analysis. Furthermore, organoids can also be exploited to explore the possible optimized treatment strategies for each individual patient. Besides, organoid technology is a promising strategy for regeneration medicine and transplantation use, which can overcome the deficiency in the supply of healthy donor tissues and inherent immunological rejection through establishing isogenic organoids from minuscule amounts of patient biopsies. Collectively, organoids hold enormous potential for clinical applications and bring basic research closer to clinical practice. In this review, we described common organoid lines, summarized the potential clinical applications, and outlined the current limitations.

Keywords: Organoids, Development, Infectious diseases, Genetic diseases, Cancer, Drug development, Precision medicine, Regeneration medicine

Background
Two-dimensional cell line culture and animal models have long been exploited to study embryonic development and human diseases. However, diverse drawbacks make these conventional models to be suboptimal. For instance, cell lines display the inability in modeling immune system, stromal components and organ specific functions as well as the gradual loss in genetic heterogeneity of original cells after many passages [1]. Animal models possess different structures and physiology [2] as well as experience species-specific organ development and pathogenesis [3].

During the past decades, organoid technology, an innovative three-dimensional (3D) model, has risen rapidly and become more and more prevalent among researchers. Organoids are 3D tissues in miniature in vitro, which are specific to the parent counterparts in vivo [4]. These amazing 3D constructs, which can be established from embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), adult stem cells and even tumor cells in 3D culture system (Fig. 1), contain multifarious cell types of original organs and mimic the derived organs in both architecture and function to a great degree [5].

Up to now, healthy organoids have been developed successfully from various organs, such as lung [6–8], gastric [2], intestinal [9], liver [10], pancreas [10, 11], kidney [12–15], prostate [16] and brain [17, 18]. Apart from healthy organoids, organoid biobanks of multiple human cancers have also been established efficiently, including gastrointestinal cancer [19, 20], liver cancer [21], breast cancer [22] and bladder cancer [23]. Organoid technology demonstrates tremendous potential for fundamental research and clinical applications (Fig. 2). Firstly, organoids can be employed to model and study organ development [24]
and human diseases, as exemplified by genetic conditions [25, 26], infectious diseases [27, 28] and tumors [29, 30]. Secondly, organoids can be exploited as an excellent platform to evaluate drug efficacy [31] and toxicity [32], ultimately promoting drug development. Thirdly, precision medicine might be another pivotal branch of organoid technology by accurately predicting drug responses [33] and guiding to make optimized treatment strategies for each patient individual. Finally, organoids show regeneration potential after transplantation to animals [34, 35], signifying that it can serve as an alternative approach to tissue replacement strategy for irreversibly progressively diseased or non-functional organs.

In this review, we describe diverse organoid types and focus on potential applications, including organ development, disease modeling, drug development, precision medicine and regeneration medicine. Finally, we outline the current limitations of this amazing technology.

**Current organoid technology**

Multiple types of organoids have been efficiently established in specific 3D culture system, including lung organoids [6], gastric organoids [36, 37], intestinal organoids [9], liver organoids [38], pancreatic organoids [39], prostate organoids [16] and brain organoids [40]. The distinct culture components for diverse organoids were displayed in Table 1.

**Lung organoids**

Lung organoids have been successfully established in multiple studies [6–8, 41, 42]. Following definitive endoderm induction and anteriorization through manipulation of developmental signaling pathways, human pluripotent stem cells (hPSCs) ultimately formed lung bud organoids (LBO) with branching morphogenesis in Branching media and Matrigel [7]. In human lung organoids, it was observed that smooth muscle and myofibroblasts surrounded upper airway-like epithelial with immature ciliated cells and basal cells as well as a distal alveolar-like section [8]. In addition, human alveolar epithelial progenitors together with lung fibroblasts, cultured in SAGM media (all additives without epinephrine) and growth factor-reduced Matrigel (phenol-free), developed into functional alveolar epithelial, containing alveolar type 1 (AT1) and AT2 cells [6]. Besides, through regular modulation of the canonical Wnt signaling,
iPSCs can finally develop into functional proximal airway organoids via NKX2-1+ progenitors [42]. The airway organoids only contain epithelial section with multiple airway epithelial cell types, including ciliated, goblet and basal cells [42]. In another study, combination culture of human somatic primary bronchial epithelial cells, lung fibroblasts and lung microvascular endothelial cells, also led to the generation of airway organoids in Matrigel and...
Pneumacult-ALI Maintenance/Complete Base Medium, in which there were invasive multicellular luminal structures [41].

**Gastric organoids**

Gastric organoids have been efficiently developed in various researches [2, 36]. McCracken and colleagues unprecedentedly reported the de novo establishment of human gastric organoids from hPSCs [36]. Following definitive endoderm induction and foregut spheroid generation, floating foregut spheroids were cultured in specific 3D culture system [36]. It was demonstrated that combination treatment of Wnt3A, fibroblast growth factor 4 (FGF4) and Noggin (a bone morphogenetic protein inhibitor) directed definitive endoderm to foregut, and retinoic acid promoted the conversion from posterior foregut spheroids to sex determining region Y-box 2 (SOX2)/pancreatic and duodenal homeobox 1 (PDX1)+ antrum epithelial [36]. In another study, single adult Lgr5+ stem cells isolated from gastric gland units can also develop into gastric organoids [37]. For avoiding anoikis, the Rho kinase inhibitor Y-27632 was added during the first 2 days after seeding [37]. For direction to enteroendocrine lineage, Exendin 4 was supplemented [37]. These long-lived gastric organoids resembled mature pyloric epithelium, in which newly formed pyloric-like structure was a single-layered epithelial containing a central glandular lumen full of apoptotic cells surrounded with gastric gland-domain buds [37]. The organoids still maintained this property even during the ninth month of culture with the expression of gastric epithelial markers including gastric intrinsic factor, pepsinogen C and mucin 6 [37].

**Intestinal organoids**

The technology to establish intestinal organoids have been developed [9, 43–47]. IPSCs-derived intestinal organoids contained diverse intestinal cells, including intestinal stem cells, enterocytes, goblet cells, enteroendocrine cells, paneth cells, fibroblasts and smooth muscle cells [47]. In addition, intestinal markers and pharmacokinetically related genes were detected, and some structural features (microvilli and tight junctions) were observed in organoids [47]. Furthermore, these organoids expressed

---

**Table 1 Culture systems of multiple organoids**

| Organoid type                  | Sources                                         | Culture components                                                                 | Ref. |
|--------------------------------|-------------------------------------------------|-------------------------------------------------------------------------------------|------|
| Lung                           | Lung alveolar epithelial cells (together with lung fibroblasts) | Matrigel, SAGM medium with all additives except epinephrine (Y27632 was added during the first 2 days. Wnt3A, FGF7, FGF10, XAV939 and CHIR99021 were added after the first 2 days) | [6]  |
| Gastric                        | hPSCs                                           | Matrigel, Advanced Dulbecco’s modified Eagle’s medium (DMEM/F12 with N2, B27, l-glutamine, HEPES, penicillin/streptomyacin and EGF (Retinoic acid and Noggin were added for the first 3 days) | [36] |
| Lgr5+ stem cells               | Matrigel, Advanced DMEM/F12 with N2, B27, N-acetylcysteine, Gastrin, and EGF, R-spondin-1, Noggin, FGF10 and Wnt3A (Y-27632 was added for the first 2 days, and Exendin 4 was added for the differentiation of enteroendocrine lineage) | [37] |
| Intestinal                     | ESCs and iPSCs                                  | Matrigel, Advanced DMEM/F12, N2, B27, l-glutamine, HEPES, penicillin/streptomyacin, EGF and Noggin | [9]  |
| Liver                          | iPSCs                                           | Matrigel, Hepatocyte culture medium supplemented with dexamethasone, oncostatin M, hepatocyte growth factor and SingleQuots | [38] |
| Pancreas                       | Pancreatic progenitor from hPSCs                | Matrigel, MCD1311, glucose, sodium bicarbonate, FAF-bovine serum albumin, l-glutamine, l-ascorbic acid, FGF2, Y27632, insulin–transferrin–selenium–ethanolamine, nicotinamide, FGF10, glucose, docetaxel V and the transforming growth factor β-receptor inhibitor SB431542 | [39] |
| Prostate                       | Luminal and basal prostatic epithelial lineages | Matrigel, Advanced DMEM/F12, penicillin/streptomyacin, GlutaMAX and Hepes, B27, N-acetylcysteine, EGF, the transforming growth factor-beta inhibitor A-83-01, Noggin, R-spondin-1, dihydrotestosterone, nicotinamide, FGF2, FGF10, SB202190 and prostaglandin E2 (Y-27632 is added when passaging with Tryple) | [16] |
| Brain                          | ESCs                                            | Matrigel, Advanced DMEM/F12, FGF2, insulin, Shh signaling inhibitor, bone morphogenetic protein, Y-27632, SB431542, FGF19 and stromal cell-derived factor 1 | [40] |
drug transporters, and showed efflux transport activity and the activation of the drug-metabolizing enzyme cytochrome P450 [47]. Human colon organoids have been successfully developed from hPSCs [9]. Colon organoids contained multiple colon-typical cell population, including goblet cells and enteroendocrine cells [9]. After transplantation into mice, colon organoids experienced morphogenesis and maturation to form tissues, which greatly resembled human colon in molecular, cellular and morphologic properties [9]. Organoids contained more cells with enhanced expression of preproglucagon, peptide YY and colon specific hormone insulin-like 5 [9].

Liver organoids
Liver organoids have been established successfully in a flurry of studies [10, 21, 38, 48–50]. Broutier’s group summarized a detailed protocol of an in vitro 3D culture system for human liver organoids [10]. When transferred from expansion median to differentiation median, liver organoids were endowed with functional hepatocyte characteristics of albumin production, bile acid production and cytochrome activity as well as enhanced expression of typical hepatocyte markers including albumin, cytotoxins and α-1-antitrypsin [10]. IPSCs can also develop into liver organoids under proper conditions [38]. Following the induction of hepatic endoderm from human iPSCs, the hepatic endoderm together with human umbilical vein endothelial cells and human meseenchymal stem cells were cultured in specific culture system and ultimately formed liver organoids [38]. After transplanted into the cranial window of non-obese diabetic/severe combined immunodeficient mouse, the liver buds efficiently connected to host vascular networks in vivo, which was essential to the liver bud maturation [38]. Interestingly, the transplants displayed function maturation, including the production of albumin and human serum α-1-antitrypsin as well as drug metabolism activity in ketoprofen and debrisoquine [38].

Pancrea organoids
In several studies, pancreatic organoids have been successfully established [10, 11, 39, 51]. A subgroup of progenitor cells with high aldehyde dehydrogenase (ALDH) activity ALDH<sup>high</sup> formed organoids more efficiently with high expression of pancreatic progenitor markers, such as PDX1, pancreas associated transcription factor 1a, carboxypeptidase A1 and MYC in comparison with ALDH<sup>low</sup> cells [11]. The differentiation to insulin-positive cells was observed after the organoids were transplantation into immunodeficient mice [11], and insulin was expressed accompanied with several functional endocrine markers of PDX1, islet amyloid polypeptide, NKX6.1 and synaptophysin [11]. In another study, pancreatic progenitor cells derived from hPSCs formed pancreatic organoids with the expression of exocrine markers (amylase and chymotrypsin C), ductal markers (SOX9 and cytokeratin 19 (CK19) and cystic fibrosis transmembrane conductance regulator), the epithelial marker E-cadherin and the progenitor marker NKX6.1 [39]. In terms of structures, these organoids displayed specific ductal morphology with microvilli and tight junction, and contained a hollow central tubular structure with a basal lamina and apical-basal polarity [39]. At functional level, carbonic anhydrase activity and enzymatic activity of amylase, trypsin and elastase were detected in the pancreatic organoids [39].

Prostate organoids
The establishment of prostate organoids has been described in several studies [16, 52, 53]. A previous research reported a well-defined protocol to develop prostate organoids for long term from luminal and basal prostatic epithelial lineages [16]. Chua CW and colleagues showed the generation of prostate organoids from single luminal progenitor cells in the absence of stroma [52]. HPSCs-derived prostate organoids displayed a network of epithelial-like ducts, which consisted of monolayer epithelium with a central lumen and encircled basement membrane and stromal cells [53]. These organoids exhibited prostatic-like structures with typical expression of prostate specific antigen and androgen receptor as well as the capacity of response to testosterone and production of secretory proteins [53].

Brain organoids
Human brain was an intricate organ and many physiological and pathological processes remain elusive. Brain organoids have been developed and hold great potential to reveal the complex process of development and abnormality. Up to now, a variety of neural organoids [17, 54] have been generated including the whole brain [24, 55–59] and sub-brain regions [60], such as of hypothalamus [61], adenohypophysis [62], midbrain [63], cerebellum [40] and hippocampus [64].

Mouse ESCs-derived adenohypophysis organoids have been developed with similar structure and specific function [62]. ESCs with hedgehog signaling organoids were promoted to differentiate to hypothalamic neuroectoderm, and various endocrine cells were produced [62]. In response to corticotrophin releasing hormone, the corticotrophs secreted adrenocorticotropic hormone in reaction [62]. Midbrain organoids from PSCs have been reported by Jo J’s group [63]. These organoids contained different layers of neuronal cells with the expression of midbrain-specific markers of homeobox transcription factor 1 alpha,
CORIN, forkhead box A2 and orthodenticle homeobox 2 (OTX2), and it was observed that there were functionally mature midbrain dopaminergic neurons and dopamine production in the midbrain-like 3D structures [63]. In addition, these organoids produced neuromelanin-like granules that structurally mimicked those in human nigra tissues [63].

Human ESC-derived cerebellum organoid model was successfully built through chemically-defined 3D culture system [40]. Following dissociation and reaggregation, robust differentiation of the aggregates to nerve was observed with the expression of midbrain-hindbrain markers after 2 weeks [40]. FGF2 exposure inhibited the forebrain markers OTX2 and sine oculis homeobox homolog 3, but upregulated FGF8 and WNT1 [40]. Until 21 days, the hESC aggregates were transferred from 96-well plate to petri dish [40]. Subsequently, hESCs with FGF2 treatment expressed kirre like nephrin family adhesion molecule 2, which was one of the earliest markers for cerebellar plate neuroepithelium [40].

Mellios’s group employed human cerebral organoids to reveal deficits in neuronal migration and neurogenesis in neural progenitors with the deficient of methyl-CpG binding protein 2 [65]. It has been recently reported that vascularized brain organoids were successfully generated from a patient’s own iPSCs by Pham MT’s group [66].

**Application of organoid technology**

**Organoids in the study of tissue development**

Organoids hold great promise for basic biomedical research. This novel tool has now enabled researchers to study in vitro organogenesis, lineage specification and tissue homeostasis. Induced human intestinal organoids (iHIOs) can be generated to mimic the human intestine through exposure to a series of growth factors to mimic embryonic intestinal development [67]. Activin-A induces definitive endoderm formation, FGF/WNT induces posterior endoderm patterning, hindgut specification, and morphogenesis. FGF/WNT also promotes a pro-intestinal culture system to encourage intestinal growth, morphogenesis, and cytodifferentiation. After 28 days in culture, iHIOs were found to express intestinal stem cell markers and consist of polarized, columnar epithelium patterned into a villus-like structure that collectively exhibited similar morphology to human intestinal epithelium [68].

McCracken et al. reported that the development of human gastric organoids extremely resembled stomach organogenesis in vivo, experiencing a series of critical stages including definitive endoderm induction, posterior foregut specification and anterior gut tube formation, specification and patterning into fundus or antrum, and epithelial growth and differentiation [36]. One month-old organoids remarkably resembled human fetal stomach tissues in transcriptional profile, and contained surface mucous cells with mucin 5AC expression, mucin 6+ antral gland cells, SOX9+ proliferative progenitor zone, Lgr5+ cells and endocrine cells [36]. It was observed that high levels of epidermal growth factor (EGF) inhibited the expression of neurogenin 3 (NEUROG3) (a pro-endodocrine transcription factor) and suppressed endocrine cell formation, while low level of EGF or NEUROG3 overexpression promoted the differentiation of endocrine cells in gastric organoids [36]. LBOs derived from hPSCs, containing mesoderm and pulmonary endoderm, formed branching airway and early alveolar architectures in 3D culture system [7]. According to expression and structural analyses, the branching structures in LBOs are tantamount to fetal lung at the mid-term of human gestation [7]. Human neural organoids from embryonic stem cells were established in the rotary cell culture system to explore whether microgravity affected the generation and maintenance of these organoids [69]. The results showed that neural organoids could be successfully generated and maintained in the condition of microgravity, but there were still some changes in the level of cortical markers and rostral-caudal neural patterning genes relative to the organoids generated in standard conditions [69].

**Organoids in disease modelling**

**Infectious disease**

Respiratory tract infection in infants is mainly caused by respiratory syncytial virus, tropism of which includes human alveolar epithelial cells and ciliated cells [70]. Human airway epithelial cells infected with respiratory syncytial virus swell and detach from the epithelium, and the detached cells contribute to obstruction of small airways which is a common manifestation of this infectious disease [70, 71]. It has been demonstrated that infecting hPSC-derived LBOs with respiratory syncytial virus contributed to swelling and detachment as well as shedding of infected cells into organoid lumens, which resembled the phenomenon observed in human lungs [7].

The popular organoid technology facilitates the investigation of the interaction between the gastrointestinal and enteric viruses [72]. It has been demonstrated that gastric organoids can be employed to model the pathophysiologic response of stomach to *Helicobacter pylori* infection [36]. Microinjection of *Helicobacter pylori* into the epithelial lumen of gastric organoid induced epithelial response, including remarkable phosphorylation of c-Met and robustly enhanced proliferation [36]. In addition, *Helicobacter pylori* virulence factor cytotoxin associated gene A (CagA) translocated into epithelial cells and combined with c-Met receptor [36]. When infected with a strain of *Helicobacter pylori* without...
CagA, organoids were nonreactive to the infection with no epithelial response [36]. These phenomena revealed that CagA was critical for *Helicobacter pylori*-mediated pathophysiological responses in gastric organoid [36].

Recently, Baktash and his colleagues employed polarized hepatoma organoids to mimic the entry of hepatitis C virus (HCV) to hepatocytes, revealing that HCV engage and enter host cells through an active and multi-step procedure [73]. HCV firstly localized with the entry factors scavenger receptor B1, cluster of differentiation 81 and epidermal growth factor receptor (EGFR), and subsequently actin-dependently gathered at the tight junction [73]. Furthermore, HCV associated with another two factors claudin-1 and occludin at the tight junction and enter into hepatocytes through clathrin-mediated endocytosis in a dynamic process requiring EGFR [73].

Zika virus (ZIKV) infection can contribute to some severe syndromes, including Guillain–Barré syndrome and congenital Zika syndrome [74]. ZIKV can infect and destroy cells from central nervous system, including neurons, progenitors and glial cells [74]. Neural progenitor cells are particularly vulnerable to ZIKV infection, which results in neurogenesis impairment, cell death and ultimately microcephaly after birth [74]. ZIKV-infected cerebral organoids have been propagated by Novitch BG and colleagues [59]. After ZIKV infection, widespread progenitor apoptosis and whole growth restriction were observed, and inflammatory responses were switched on in direct and indirect manners in organoids, resulting in neurodegeneration [59].

**Genetic disease**

Organoids can serve as an extraordinary platform for the study of the biology of some genetic diseases. For instance, retinitis pigmentosa is an inherited and irreversible disease, and majorly caused by mutations in *PRGR* gene [75]. Patient-derived retinitis pigmentosa organoids harboring *PRGR* mutations have been developed from iPSCs, and faithfully recapitulated the defects of morphology, localization, transcriptional profiling and electrophysiological activity in photoreceptor as well as shorted cilium [75].

Considering that *disrupted in schizophrenia 1 (DISC1)* interruption had been implicated in mental illness, Srirkanth and his colleagues employed the 3D model to investigate the role of DISC1 in psychiatric disease [76]. They developed cerebral organoids from DISC1-disrupted and isogenic wild-type human pluripotent stem cells, respectively [76]. DISC1-mutant organoids exhibited disorganized structural morphology and weakened proliferation with changes of cell fate markers, interneuron markers and regulators of neuronal migration [76].

**Hermansky–Pudlak syndrome 1 (HPS1)** mutation partly accounts for the formation of intractable pulmonary fibrosis [7]. Introduction of *HPS1* mutation to LBOs formed lung organoids with lung fibrosis, in which extra-cellular matrix and mesenchymal cells accumulated [7]. This observation signifies that organoids can serve as a potential model to recapitulate fibrotic lung disease.

**Cancer**

Organoids have tremendous promise for modelling human cancers and exhibit their utility for translational and clinical cancer research [77, 78]. Up to now, organoids have been successfully developed from multiple cancer types, including gastric cancer [19, 20], intestinal cancer [19], liver cancer [21], pancreatic cancer [79–81], prostate cancer [82–84], bladder cancer [23] and breast cancer [22, 85].

Gastric cancer organoids faithfully recapitulate important characteristics of the corresponding parent tumors as exemplified by architectures, the expression of typical gastric cancer markers and the presence of various prevalent mutations in gastric cancer [20]. In addition, colorectal cancer organoids showed remarkable resemblance with the primary tumors in the aspects of morphology, mutational landscape and transcriptomic profiling [19]. Broutier and colleagues demonstrated that primary liver cancer organoids retained typical architectures and similar transcriptomic profiles to parent tumors [21]. Seino et al. detected pancreatic carcinoma-related gene alterations in corresponding tumoroids, and observed tumor formation that resembled the derived cancer in organoid transplants [79].

Gao’s group demonstrated that there were a diversity of characteristic copy number alterations and mutations detected in both organoid lines and corresponding parent prostate cancer as well as similar histological patterns in organoid xenoplants [82]. When transplanted into mice, these organoid lines displayed histological patterns found in parent tumors [82]. Histological analyses on bladder cancer organoids reported not only the remarkable resemblance in mutational profiles between these organoids and the corresponding derived tumors, but also cancer evolution with some genomic changes in vitro [23]. Besides, breast cancer organoid lines also resembled the parent tumors in morphology, histopathology and gene profiles [22].

**Organoids in drug development and precision medicine**

As near-physiological architectures, organoids faithfully recapitulate the primary tumors and can faithfully recapitulate drug responses [19, 20, 33, 86, 87] as well as even help optimize therapy strategies for each patient individual. Healthy organoids can be exploited to assess the drug
toxicity, such as hepatotoxicity experimental compounds [32, 88, 89], cardiotoxicity [87, 90] and nephrotoxicity [91].

**Infectious diseases**

Drug testing has been conducted in ZIKV-infected cortical organoids [59]. 25-hydroxycholesterol (25HC), which obstructs viral entry through suppressing membrane fusion, was assessed in the infectious organoid models [59]. After the addition of 25HC to organoid cultures, both ZIKV mRNA and whole number of ZIKV positive cells dramatically decreased among organoids, with no amelioration on cell death [59]. Considering that inhibition or competitive combination of the AXL receptor on neural progenitors can restrict ZIKV entry or spread, the molecular inhibitor of AXL (R428) or the antibodies to AXL have also been tested in organoids, showing that R428 had mild negative effects on ZIKV mRNA level but antibody treatment had no significant effects on ZIKV mRNA level [59]. Administration of duramycin or ivermectin remarkably decreased ZIKV mRNA and ZIKV envelope protein positive cells, but azithromycin can not reduce the level of ZIKV expression [59]. The results indicated that cortical organoids can be employed to distinguish drugs for ZIKV infection in developing human nervous system and identified promising compounds.

**Genetic diseases**

Cystic fibrosis (CF) organoids have been successfully established to explore potential therapy strategies for patients [26, 39, 92]. Compound screen using organoid as a platform, indicated that two types of small-molecule compounds, including cystic fibrosis transmembrane conductance regulator (CFTR) correctors for improving cellular processing and CFTR potentiators for gating function of the CFTR protein, effectively significantly rescued CF phenotype [39]. Furthermore, it was also demonstrated that the modification of chemically modified mRNA supplemented CFTR gene and restored CFTR function in organoids [39]. Therefore, the newly spring-up culture system represents a novel approach to drug screening for genetic diseases.

**Cancer**

Recently, metastatic gastrointestinal cancer organoids have been exploited to assess the potential of the novel technology in prediction of treatment response among patients [19]. The results demonstrated that these organoids could faithfully recapitulate treatment responses of gastrointestinal cancers with high sensitivity (100%) and specificity (93%) [19]. In addition, Therese Seidlitz’s group identified that human gastric cancer organoids recapitulated the distinct responses to conventional chemotherapeutics [20]. According to another study, the combination of navitoclax (a preclinical B-cell CLL/lymphoma 2 (BCL2)/BCLXL inhibitor), afatinib and selumetinib potently induced cell death in comparison with monotherapy of these drugs, signifying a possible alternative treatment strategy for colorectal cancer patients [93]. In accordance with clinical observation, androgen receptor (AR)-amplified prostate cancer organoids responded efficiently to the AR inhibitor enzalutamide, while AR-negative prostate cancer organoids were insensitive to this drug [82]. Apart from testing the efficacy of a known therapy, organoid lines can also be employed to test the effectiveness of treatment on unknown mutations. For instance, imatinib treatment was effective for an unknown mutation in exon 3 of the c-KIT receptor [20].

Organoid technology exerts enormous potential in precision medicine. According to Rubin’s study, the combination therapy of vorinostat and buparlisib is the most effective for uterine carcinosarcoma patients harboring driver mutations in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and phosphatase and tensin homolog (PTEN) among all combination strategies, and the treatment of buparlisib plus olaparib displayed strongest anti-tumor effects in the endometrial adenocarcinoma organoids organoid with mutations in PIK3CA and PTEN [94]. For late-stage colorectal cancer with KRAS and TP53 mutations, the treatment of trametinib and celecoxib was the most effective combinational strategy [94]. In addition, the combination therapy of hedgehog signal inhibitors plus 5-fluorouracil (5-FU) or irinotecan exerted strong anti-tumor effects for 5-FU or irinotecan-resistant colorectal cancer organoids [95], signifying that hedgehog signal inhibitors were effective combinational candidates for colorectal cancer patients with resistance to 5-FU or irinotecan.

**Regeneration medicine**

Modern regeneration medicine aims to replace the diseased tissues with corresponding healthy tissues through allogenic transplantation. However, the deficiency in the supply of healthy donor tissues and the inherent immunological rejection pose challenges to the survival and function of transplanted tissues in recipient patient body for long term. Organoid technology endows researchers with the ability of developing isogenic or human lymphocyte antigen-matched organoids from minuscule amounts of patient biopsies or readily accessible tissues.

Many studies have demonstrated the potential of organoid technology to provide an alternative approach to organ replacement strategies for several tumor types. Following transplantation to mice harboring colonic injury, colonic epithelium was observed in mature
intestinal organoids with the formation of epithelial crypt-like architectures and the expression of region-specific differentiation markers, leading to colon repair after injury [96]. When transplanted into mice experiencing acute liver failure, liver organoids generated from umbilical cord-derived endothelial and mesenchymal cells as well as the endothelial cell-derived human iPSC dramatically rescued the hepatic functions and enhanced the survival of diseased mice [34]. Human cholangiocytes, which were isolated and propagated from the biliary tree, reconstructed extrahepatic cholangiocyte organoids which were quite similar to the parent counterparts in ultrastructure, transcriptomic profile and functional properties [97]. After transplantation under the kidney capsule of mice, organoids formed tubular architecture with the expression of the key biliary marker CK19 [97]. Vascularization is an essential event for maturation and function of organoids in vivo. It has been reported that host-derived vascularization formed in iPSC-derived kidney organoids in fully defined conditions without any exogenous vascular endothelial growth factor. Progressive morphogenesis, including functional glomerular perfusion in function as well as connection to pre-existing vascular system, glomerular basement membrane and fenestrated endothelial cells in structure, was observed in these organoids after transplanted under the kidney capsule [35].

Additionally, organoid technology also represents an alternative approach for degeneration diseases, as exemplified by retinal degeneration and blindness, which was enlightened by encouraging stem cell-based treatment clinical trials that focused on the replacement therapy of degenerated retinal cell types with stem cells [98]. Finally, patient organoids harboring genetic defects can be repaired by modern genome-editing techniques in vitro to generate healthy organoids and subsequently transplanted back into patients for transplantation use. Dekkers’s group utilized clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) gene editing to correct CFT1 mutations in intestinal organoids from CF patients to generate healthy organoids [26]. Another example is retinitis pigmentosa organoid, in which correction of retinitis pigmentosa guanosine triphosphatase regulator mutation through CRISPR-Cas9 technique normalized gene expression, rectified photoreceptor structure, and reversed electro-physiological property [75].

**Current limitations**

Current organoid technology still represents an imperfect version. Firstly, organoids only contain epithelial layer without tissue microenvironment, such as immune system and nervous system [86]. Secondly, fully maturation to adult organs or tissues is a bottleneck required to be addressed. Thirdly, another limitation is the dependence on the extracellular matrix Matrigel or basement membrane extract of current organoids, which is produced from mouse tumor lines and thus might be unsuitable for human. Matrigel could also hamper drug penetration and be adverse to the potential of organoids in drug screens. Fourthly, culture medium needs to be further refined for long-term expansion of some organoids. Fifthly, growth factors or molecular inhibitors in culture medium might have some effects on drug responses of organoids. Further efforts will be urgently exerted to solve these problems.

**Conclusion**

In spite of current limitations, this promising organoid technology holds great potential in accurately modelling organ development and human diseases, and it can serves as an extraordinary platform for therapy response-prediction, drug development and personalized medicine. Furthermore, organoid technology represents an excellent alternative for transplantation use. Future efforts will doubtless improve this novel tool for clinical application.

**Abbreviations**

ALDH: aldehyde dehydrogenase; AR: androgen receptor; AT1: alveolar type 1; BCL2: B cell CLL/Lymphoma 2; CagA: cytotoxin associated gene A; Cas9: CRISPR-associated protein 9; CF: cystic fibrosis; CFT1: cystic fibrosis transmembrane conductance regulator; CK19: cytokeratin 19; CRISPR: clustered regularly interspaced short palindromic repeats; DISC1: disrupted in schizophrenia 1; DMEM: Dulbecco’s modified Eagle’s medium; EGF: epidermal growth factor; EGFR: epidermal growth factor receptor; ESCs: embryonic stem cells; FGF4: fibroblast growth factor 4; HCV: hepatitis C virus; HPS1: Hermansky–Pudlak syndrome 1; hPSCs: human pluripotent stem cells; iHIOs: induced human intestinal organoids; iPSCs: induced pluripotent stem cells; LBO: lung bud organoids; NEUROG3: neurogenin 3; OTX2: orthodenticle homeobox 2; PDX1: duodenal homeobox 1; PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PTEN: phophatase and tensin homolog; SOX2: sex determining region Y-box 2; ZIKV: zika virus; 25HC: 25-hydroxycholesterol; 3D: three-dimensional; 5-FU: 5-fluourouracil.

**Authors’ contributions**

HX performed the selection of literature, drafted the manuscript and prepared the figures. YJ, SQ and WZ collected the related references. QC and KW carried out the design of this review and revised the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Availability of data and materials**

Not applicable.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.
Funding
This work was supported by the National Natural Science Foundation of China (Nos. 81572608, 81874120 and 81672984), and supported by Wuhan Science and Technology Bureau (No. 20170602010170).

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 21 October 2018   Accepted: 29 November 2018
Published online: 05 December 2018

References
1. Zhou J, Su J, Fu X, Zheng L, Yin Z. Microfluidic device for primary tumor spheroid isolation. Exp Hematol Oncol. 2017;6;22.
2. Eicher AK, Berns HM, Wells JM. Translating developmental principles to generate human gastric organoids. Cell Mol Gastroenterol Hepatol. 2018:5;353–63.
3. Ben-David U, Ha G, Tseng YY, Greenwald NF, Oh C, Shih J, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017;49:1567–75.
4. Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. J Hematol Oncol. 2018;11:116.
5. Lancaster MA, Knoblich JA. Organogenesis in a dish: modelling development and disease using organoid technologies. Science. 2014;345:1247125.
6. Zacharias WJ, Frank DB, Zepp JA, Morley MP, Alkhaleel FA, Kong J, et al. Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor. Nature. 2018;555:251–5.
7. Chen YW, Huang SX, de Carvalho A, Ho SH, Islam MN, Volpi S, et al. A transient activation of BMP signaling. Cell Stem Cell. 2017;21(51–64):e6.
8. Dye BR, Hill DR, Ferguson MA, Tsai YH, Nagy MS, Dyal R, et al. In vitro generation of human pluripotent stem cell derived lung organoids. Elife. 2015;4:e05098.
9. Munera JO, Sundaram N, Rankin SA, Hill D, Watson C, Volpi S, et al. Differentiation of human pluripotent stem cells into colonic organoids via transient activation of Wnt signaling. Cell Stem Cell. 2017;21(51–64):e6.
10. Broutier L, Andersson-Rolf A, Hindley CJ, Boj SF, Clevers H, Koo BK, et al. Strong differentiation of human pluripotent stem cells into colonic organoids via transient activation of Wnt signaling. Cell Stem Cell. 2017;21(51–64):e6.
11. Loomans CJM, Williams Giuliani N, Balak J, Ringnalda F, van Gurp L, Huch M, et al. Human pluripotent stem cell-derived human intestinal organoids as an infection model for rotavirus. mBio. 2012;3:e00159-12.
12. Castellanos-Gonzalez A, Cabada MM, Nichols J, Gomez G, White AC Jr. Human primary intestinal epithelial cells as an improved in vitro model for Coxsackievirus. J Virol. 2014;8;124:328–37.
13. Dekkers JF, Wiegerink CL, de Jonge HR, Borsveld J, Janssens HM, de Winter-de Groot KM, et al. A functional CTR assay using primary cystic fibrosis intestinal organoids. Nat Med. 2013;19:939–45.
14. Finfbeiner SR, Zeng XL, Utama B, Atmar RL, Shroyer NF, Estes MK. Stem cell-derived human intestinal organoids as an infection model for rotaviruses. mBio. 2013;4:e00159-12.
15. Yeung TM, Gandhi SC, Wilding JL, Bodmer WF. Stem cell-derived lung organoids as a 3D platform for modelling human lung development and disease. Gut. 2017;66:473–86.
16. Meng Q. Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol. 2010;6:733–46.
17. Abbasi J. Patient-derived organoids predict cancer treatment response. JAMA. 2018;319:1427.
18. Nie YZ, Zheng YW, Ogawa M, Miyagi E, Taniguchi H. Human liver organoids generated with single donor-derived multiple cells rescue mice from acute liver failure. Stem Cell Res Ther. 2018;9:5.
19. van den Berg CW, Ritsma L, Avramut MC, Wiersma LE, van den Berg BM, van den Berg BM, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013;501:373–9.
20. Vlahogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920–6.
21. Seidelitz T, Merker SR, Rothe A, Zakrzewski F, von Neubeck C, Grutzmann K, et al. Human gastric cancer modelling using organoids. Gut. 2018;67:665–76.
22. Broutier L, Mastrogianni G, Versteeg FM, Francis HE, Gavaro LM, Bradshaw CR, et al. Human primary liver cancer-derived organoids cultures for disease modelling and drug screening. Nat Med. 2017;23:1424–35.
23. Sachs N, de Ligt J, Kopper O, Gogola M, Bouwena G, Weeber E, et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell Rep. 2018;17(2373–86):e110.
24. Lee SH, Hu W, Matulay JT, Silva MV, Ovczarek TB, Kim K, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell. 2018;173(515–28):e17.
25. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, et al. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501:373–9.
26. Bigorgne AE, Farin HE, Lemoine R, Mahlaoui N, Lambert N, Gil M, et al. TTC7A mutations disrupt intestinal epithelial apicobasal polarity. J Clin Invest. 2014;124:328–37.
27. Finkbeiner SR, Zeng XL, Utama B, Atmar RL, Shroyer NF, Estes MK. Stem cell-derived human intestinal organoids as an infection model for rotavirus. mBio. 2012;3:e00159-12.
28. Castellanos-Gonzalez A, Cabada MM, Nichols J, Gomez G, White AC Jr. Human primary intestinal epithelial cells as an improved in vitro model for Coxsackievirus. J Virol. 2014;8;124:328–37.
29. van de Wetering M, Frances HE, Francis JM, Bounova G, Iorio F, Pronk A, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161:933–45.
30. Meng Q. Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol. 2010;6:733–46.
31. Abbasi J. Patient-derived organoids predict cancer treatment response. JAMA. 2018;319:1427.
32. Nie YZ, Zheng YW, Ogawa M, Miyagi E, Taniguchi H. Human liver organoids generated with single donor-derived multiple cells rescue mice from acute liver failure. Stem Cell Res Ther. 2018;9:5.
33. van den Berg CW, Ritsma L, Avramut MC, Wiersma LE, van den Berg BM, Leuning DG, et al. Renal subcapsular transplantation of PSC-derived kidney organoids. Proc Natl Acad Sci USA. 2010;107:3722–7.
34. Onuma K, Ochiai M, Onihashi K, Takahashi M, Imai T, Nakagama H, et al. Genetic reconstitution of tumorigenesis in primary intestinal cells. Proc Natl Acad Sci USA. 2013;110:11127–32.
35. van de Wetering M, Frances HE, Francis JM, Bounova G, Iorio F, Pronk A, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161:933–45.
36. Meng Q. Three-dimensional culture of hepatocytes for prediction of drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol. 2010;6:733–46.
37. Vlahogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359:920–6.
38. Seidelitz T, Merker SR, Rothe A, Zakrzewski F, von Neubeck C, Grutzmann K, et al. Human gastric cancer modelling using organoids. Gut. 2018;67:665–76.
stem cells via temporal regulation of Wnt signaling. Cell Stem Cell. 2017;20:844–57.e6.
43. Zhang RR, Kodio M, Dadokoro T, Ouchi R, Matsuno T, Ueno Y, et al. Human iPSC-derived posterior gut progenitors are expandable and capable of forming gut and liver organoids. Stem Cell Rep. 2018;10:780–93.
44. Zhang D, Tan M, Zhong W, Xia M, Huang P, Jiang X. Human intestinal organoids express histo-blood group antigens, bind norovirus VLPs, and support limited norovirus replication. Sci Rep. 2017;7:2621.
45. Miura S, Suzuki A. Generation of mouse and human organoid-forming intestinal progenitor cells by direct lineage reprogramming. Cell Stem Cell. 2018;24(5):578–91.e5.
46. Jung KB, Lee H, Son YS, Lee JH, Cho HS, Lee MO, et al. In vivo and in vitro imaging and tracking of intestinal organoids from human induced pluripotent stem cells. FASEB J. 2018;32:111–22.
47. Onozzo D, Yamashita M, Nakashiki A, Akagawa T, Kida Y, Ogawa I, et al. Generation of intestinal organoids suitable for pharmacokinetic studies from human induced pluripotent stem cells. Drug Metab Dispos. 2018;46:1572–80.
48. Camp JG, Sekine K, Gerber T, Loeffler-Wirth H, Binder H, Gac M, et al. Multilineage communication regulates human liver bud development from pluripotency. Nature. 2017;546:533–8.
49. Yanag y, Nakayama K, Taguchi Y, Enosawa S, Tamura T, Yoshimura K, et al. In vivo and ex vivo methods of growing a liver bud through tissue connection. Sci Rep. 2017;7:14085.
50. Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Bokkstein M, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell. 2015;160:299–312.
51. Vills ES, Drenth JP. Building pancreatic organoids to aid drug development. Gut. 2017;66:393–4.
52. Chua CW, Shibata M, Lei M, Toivanen R, Barlow LJ, Bergren SK, et al. Single luminal epithelial progenitors can generate prostate organoids in culture. Nat Cell Biol. 2014;16(9):1–4.
53. Calderon-Gierszal EL, Prins GS. Directed differentiation of human embryonic stem cells into prostate organoids in vitro and its perturbation by low-dose bisphenol A exposure. PLoS ONE. 2015;10:e0133238.
54. Zhu Y, Wang L, Yu H, Yin F, Wang Y, Liu H, et al. In situ generation of human brain organoids on a micropillar array. Lab Chip. 2017;17:2941–50.
55. Quadrolo G, Nguyen T, Mascalco EZ, Sherwood JL, Min Yang S, Berger DR, et al. Cell diversity and network dynamics in photosensitive human brain organoids. Nat Biotechnol. 2017;35:699–66.
56. Mansour AA, Goncalves JT, Floyd CW, Li H, Fernandez S, Quang D, et al. An in vivo model of functional and vascularized human brain organoids. Nat Biotechnol. 2018;36:343–41.
57. Paycha SP. Building three-dimensional human brain organoids. Nat Neurosci. 2018. https://doi.org/10.1038/s41593-018-0107-3.
58. Watanabe M, Nishiyama J, Vlahogianni N, de la Torre-Ubieta L, Tavosidis J, Kakhah BS, et al. Self-organized cerebral organoids with human-specific features predict effective drugs to combat zika virus infection. Cell Rep. 2017;21:517–32.
59. Qian X, Jacob F, Song WM, Nguyen HN, Song H, Ming GL. Generation of human brain region-specific organoids using a miniaturized spinning bioreactor. Nat Protoc. 2018;13:656–80.
60. Qian X, Nguyen HN, Song WM, Hadlino C, Ogden SC, Hammers C, et al. Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. Cell. 2016;165:1238–54.
61. Suga H, Kadoshima T, Minaguchi M, Ohgushi M, Soen M, Nakano T, et al. Self-formation of functional adenohypophysis in three-dimensional culture. Nature. 2011;480:37–62.
62. Jo J, Yao X, Sun AX, Cukuroglu E, Tran HD, Goke J, et al. Midbrain-like organoids from human pluripotent stem cells contain functional dopaminergic and neuromelanin-producing neurons. Cell Stem Cell. 2016;19:248–57.
63. Sakaguchi H, Kadoshima T, Soen M, Narii N, Ishida Y, Ohgushi M, et al. Generation of functional hippocampal neurons from self-organizing human embryonic stem cell-derived dorsomedial telencephalic tissue. Nat Commun. 2015;6:6896.
64. Mellois N, Feldman DA, Sheridan SD, Ip JPK, Kivoks S, Amoah SK, et al. Human cerebral organoids reveal deficits in neurogenesis and neuronal migration in MeCP2-deficient neural progenitors. Mol Psychiatry. 2018;23:791.
65. Pham MT, Pollock KM, Rose MD, Cary WA, Stewart HR, Zhou P, et al. Generation of human vascularized brain organoids. Neuronopt. 2018;29:583–96.
66. McGuigan AP, Setton MV. Vascularized organoid engineered by modular assembly enables blood perfusion. Proc Nat Acad Sci USA. 2006;103:11461–6.
67. Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vannonis JE, Tolle K, et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature. 2011;470:105–9.
68. Mattei C, Alshawaf A, D’Abaco G, Nagayama BA, Dottori M. Generation of human neonatal retina organoids from embryonic stem cells using the rotary cell culture system: effects of microgravity on neural progenitor cell fate. Stem Cells Dev. 2018;27:848–57.
69. Collins PL, Fears R, Graham BS. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol. 2013;372:3–38.
70. Liesman RM, Buchholz UJ, Luongo CL, Yang L, Proia AD, DeVincenzo JP, et al. RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction. J Clin Invest. 2014;124:2219–33.
71. Lank JE, Mara MA, Mihi B, Coyne CB, Good M. Stem cell-derived models of viral infections in the gastrointestinal tract. Viruses. 2018;10:124.
72. Baktash Y, Madhav A, Coller KE, Randall G. Single particle imaging of polarized hematopoietic organoids upon hepatitis C virus infection reveals an ordered and sequential entry process. Cell Host Microbe. 2018;23(382–94).e57.
73. Russo FB, Jungmann P, Beltraxo-Braca PG. Zika infection and the development of neurological defects. Cell Microbiol. 2017;19:e12744.
74. Deng WL, Gao ML, Lei XL, Lu JN, Zhao H, He KW, et al. Gene correction reverses ciliopathy and photoreceptor loss in iPSC-derived retinal organoids from retinitis pigmentosa patients. Stem Cell Rep. 2018;10:1267–81.
75. Sripathan P, Lagomarsino VN, Muratore CR, Ryu SC, He A, Taylor WM, et al. Shared effects of DSC1 disruption and elevated WNT signaling in human cerebral organoids. Transl Psychiatry. 2018;8:77.
76. Kuo CJ, Curtis C. Organoids reveal cancer dynamics. Nature. 2018;556:441–2.
77. Mushtawamy SK. Organoid models of cancer explode with possibilities. Cell Stem Cell. 2018;22:290–1.
78. Seno T, Kawaski S, Shimokawa M, Tamagawa H, Toshimitsu K, Fuji M, et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor independence during disease progression. Cell Stem Cell. 2018;22:645–67.e6.
79. Boj SF, Hwang CJ, Baker LA, Chio II, Engle DD, Corbo V, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160:324–38.
80. Zhang HC, Kuo CJ. Personalizing pancreatic cancer organoids with HPSGs. Nat Med. 2015;21:1249–51.
81. Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159:176–87.
82. Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, et al. Patient-derived organoids to model rare prostate cancer phenotypes. Nat Commun. 2018;9:2404.
83. Shenoy TR, Boysen G, Wang MY, Xu QZ, Guo W, Koh FM, et al. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair. Ann Oncol. 2017;28:1495–507.
84. Ranftl RE, Calvo F. Analysis of breast cancer cell invasion using an organotypic culture system. Methods Mol Biol. 2017;2013:578–64.
85. Jabs B, Zicgfrad FM, Park J, Wagner S, Jiang X, Jechow K, et al. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations. Mol Syst Biol. 2017;13:955.
86. Eder A, Vollert I, Hansen A, Eschenhagen T. Human engineered heart tissue as a model system for drug testing. Adv Drug Deliv Rev. 2016;96:214–24.
87. Kostadinova R, Boess F, Applegate D, Suter L, Weiser T, Singer T, et al. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol. 2013;268:1–16.
88. Katsuda T, Kawamata M, Hagiwara K, Takahashi RU, Yamamoto Y, Camargo FD, et al. Conversion of terminally committed hepatocytes to culturable
bipotent progenitor cells with regenerative capacity. Cell Stem Cell. 2017;20:41–55.

90. Voges HK, Mills RJ, Elliott DA, Parton RG, Porrello ER, Hudson JE. Development of a human cardiac organoid injury model reveals innate regenerative potential. Development. 2017;144:1118–27.

91. Takasato M, Er PX, Chiu HS, Maier B, Baillie GJ, Ferguson C, et al. Kidney organoids from human iPSCs contain multiple lineages and model human nephrogenesis. Nature. 2015;526:564–8.

92. Dekkers JF, Berkers G, Kruijswijk E, Yonek A, de Jonge HR, Janssens HM, et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med. 2016;8:344ra84.

93. Verissimo CS, Overmeer RM, Ponsioen B, Drost J, Mertens S, Verlaan-Klink I, et al. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. Elife. 2016;5:e18489.

94. Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017;7:462–77.

95. Usui T, Sakurai M, Umata K, Elbadawy M, Ohama T, Yamawaki H, et al. Hedgehog signals mediate anti-cancer drug resistance in three-dimensional primary colorectal cancer organoid culture. Int J Mol Sci. 2018;19:1098.

96. Fordham RP, Yui S, Hannan NR, Soendergaard C, Madgwick A, Schweiger PJ, et al. Transplantation of expanded fetal intestinal progenitors contributes to colon regeneration after injury. Cell Stem Cell. 2013;13:734–44.

97. Sampaziotis F, Justin AW, Tysoe OC, Sawiak S, Godfrey EM, Upponi SS, et al. Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids. Nat Med. 2017;23:954–63.

98. Ramsden CM, Powner MB, Carr AJ, Smart MJ, da Cruz L, Coffey PJ. Stem cells in retinal regeneration: past, present and future. Development. 2013;140:2576–85.